Lundbeck and Otsuka´s Brexpiprazole for Adult Patients with Schizophrenia Accepted for Review by EMA
(WorldNews Japan)

The European Medicines Agency (EMA) is expected to complete its review in the second quarter of 2018 In both short-term and long-term clinical trials involving more than 3,000 patients, brexpiprazole has shown improvement in symptoms of schizophrenia and was generally well-tolerated in adult patients H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announce that the European Medicines Agency (EMA) has accepted for review a...